Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
19/10/2012
19/10/2012
2009
|
Resumo |
Introduction: Inhibition of matrix metalloproteinases (MMPs) improves the hemodynamics during acute pulmonary embolism (APE) and oxidative stress upregulates MMPs. We compared the effects of different NO-cGMP pathway activators on APE-induced increases in MMPs. Materials and Methods: Hemodynamic and biochemical evaluations were performed in non-embolized dogs treated with saline (N = 5), and in microspheres embolized dogs receiving saline (n = 9), or nitrite (6.75 mu mol/kg i.v. over 15 min followed by 0.28 mu mol/kg/min; n = 5), or sildenafil (0.25 mg/kg; n = 5), or BAY 41-2272 (0.03, 0.1, 0.3, and 1 mg/kg/h; n = 5). Plasma thiobarbituric acid reactive substances (TBARS) concentrations were determined. Zymograms of plasma samples were performed, and in vitro antioxidant effects or inhibition of MMPs by these drugs were examined. Results: APE increased mean pulmonary artery pressure by similar to 25 mmHg. Nitrite, BAY 41-2272, or sildenafil reversed this increase by similar to 40% (P < 0.05). Similar effects were seen on the pulmonary vascular resistance. While both nitrite and sildenafil produced no systemic effects, the highest dose of BAY 41-2272 produced systemic hypotension (P<0.05). While nitrite and sildenafil blunted the increases in plasma pro-MMP-9 levels and TBARS (all P < 0.05), BAY 41-2272 produced no such effects. Nitrite and sildenafll produced in vitro antioxidant effects and inhibited MMPs only at high concentrations. BAY 41-2272 produced no such effects. Conclusions: Activation of the NO-cGMP pathway with nitrite or sildenafil, but not with BAY 41-2272, attenuates APE-induced oxidative stress and increased MMP-9 levels. These findings are consistent with the idea that NO-cGMP pathway activators with antioxidant effects prevent the release of MMP-9 during APE. (c) 2008 Elsevier Ltd. All rights reserved. Fundacao de Amparo A Pesquisa do Estado de Sao Paulo (FAPESP) Conselho Nacional de Dsenvolvimento Cientifico e Tecnologico (CNPq) |
Identificador |
THROMBOSIS RESEARCH, v.124, n.3, p.349-355, 2009 0049-3848 http://producao.usp.br/handle/BDPI/24917 10.1016/j.thromres.2008.12.006 |
Idioma(s) |
eng |
Publicador |
PERGAMON-ELSEVIER SCIENCE LTD |
Relação |
Thrombosis Research |
Direitos |
restrictedAccess Copyright PERGAMON-ELSEVIER SCIENCE LTD |
Palavras-Chave | #Acute pulmonary embolism #BAY 41-2272 #Matrix metalloproteinases #Nitric oxide #Nitrite #Oxidative stress #Pulmonary hypertension #SMOOTH-MUSCLE-CELLS #MATRIX METALLOPROTEINASES #L-ARGININE #IMPROVES HEMODYNAMICS #CANINE MODEL #HYPERTENSION #OXIDE #THROMBOEMBOLISM #SUPEROXIDE #MMP-9 #Hematology #Peripheral Vascular Disease |
Tipo |
article original article publishedVersion |